FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968620617> ?p ?o ?g. }

• W1968620617 endingPage "18" @default.
• W1968620617 startingPage "1" @default.
• W1968620617 abstract "This study comprises a group of 75 patients with moderately and far advanced pulmonary tuberculosis treated with amithiozone or with amithiozone and streptomycin and/or PAS for periods varying from six to 10 months. Amithiozone shows marked anti-tuberculous activity in vitro and in animals. A hematologic crisis is described in a patient who received 300 mg. of amithiozone daily, but whose blood was unaffected on a dosage of 150 mg. daily for a period of 11 months. In daily dosage of 150 mg. or less, amithiozone is a safe drug when administered under medical supervision and with adequate laboratory facilities. In daily dosage of 150 mg., amithiozone may be administered for prolonged periods of time. In daily dosage of 150 mg., amithiozone may cause depression of any or all of the formed elements of the blood, but these alterations are transitory and restitution occurs with continued medication. In daily dosage of 150 mg., amithiozone may cause a transient eosinophilia. These studies do not indicate any specific effect of amithiozone on the sedimentation rate with relation to regression or progression of the disease. Chronic pulmonary tuberculosis appears to be a disease characterized by hyperproteinemia and hyperglobulinemia. Amithiozone heightens or maintains the hyperproteinemia and hyperglobulinemia. Cephalin flocculation tests of 2+ and 3+, after 48 hours, are not rare under amithiozone therapy and may be reversible with continued medication. Amithiozone may occasionally be responsible for hepatic insufficiency, jaundice, and hepatomegaly, but this reaction is reversible, and the drug may be resumed when the condition has subsided. Amithiozone may cause gastrointestinal disturbances of mild to severe intensity which disappear on cessation of medication and which are less likely to recur when the drug is resumed. In daily dosage of 150 mg. per centage amithiozone, conversion of sputum, and clinical improvement was noted. This will be evaluated and reported later. Combinations of amithiozone with streptomycin and of amithiozone, streptomycin and PAS seem to show greater clinical promise than any one of these substances used alone, but the results are still to be determined." @default.
• W1968620617 created "2016-06-24" @default.
• W1968620617 creator A5023761690 @default.
• W1968620617 creator A5040118381 @default.
• W1968620617 creator A5055174006 @default.
• W1968620617 creator A5063071576 @default.
• W1968620617 date "1951-07-01" @default.
• W1968620617 modified "2023-09-25" @default.
• W1968620617 title "Tibione in the Treatment of Tuberculosis Activity, Dosage and Toxic Manifestations" @default.
• W1968620617 cites W1510487776 @default.
• W1968620617 cites W1591480519 @default.
• W1968620617 cites W1928093467 @default.
• W1968620617 cites W1973332808 @default.
• W1968620617 cites W1983457368 @default.
• W1968620617 cites W1987722702 @default.
• W1968620617 cites W2008541744 @default.
• W1968620617 cites W2022842054 @default.
• W1968620617 cites W204221216 @default.
• W1968620617 cites W2063091268 @default.
• W1968620617 cites W2152968129 @default.
• W1968620617 cites W2210332948 @default.
• W1968620617 cites W260281369 @default.
• W1968620617 doi "https://doi.org/10.1378/chest.20.1.1" @default.
• W1968620617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14840273" @default.
• W1968620617 hasPublicationYear "1951" @default.
• W1968620617 type Work @default.
• W1968620617 sameAs 1968620617 @default.
• W1968620617 citedByCount "2" @default.
• W1968620617 crossrefType "journal-article" @default.
• W1968620617 hasAuthorship W1968620617A5023761690 @default.
• W1968620617 hasAuthorship W1968620617A5040118381 @default.
• W1968620617 hasAuthorship W1968620617A5055174006 @default.
• W1968620617 hasAuthorship W1968620617A5063071576 @default.
• W1968620617 hasConcept C126322002 @default.
• W1968620617 hasConcept C141071460 @default.
• W1968620617 hasConcept C142724271 @default.
• W1968620617 hasConcept C203014093 @default.
• W1968620617 hasConcept C2780035454 @default.
• W1968620617 hasConcept C2781069245 @default.
• W1968620617 hasConcept C71924100 @default.
• W1968620617 hasConcept C90924648 @default.
• W1968620617 hasConcept C98274493 @default.
• W1968620617 hasConceptScore W1968620617C126322002 @default.
• W1968620617 hasConceptScore W1968620617C141071460 @default.
• W1968620617 hasConceptScore W1968620617C142724271 @default.
• W1968620617 hasConceptScore W1968620617C203014093 @default.
• W1968620617 hasConceptScore W1968620617C2780035454 @default.
• W1968620617 hasConceptScore W1968620617C2781069245 @default.
• W1968620617 hasConceptScore W1968620617C71924100 @default.
• W1968620617 hasConceptScore W1968620617C90924648 @default.
• W1968620617 hasConceptScore W1968620617C98274493 @default.
• W1968620617 hasIssue "1" @default.
• W1968620617 hasLocation W19686206171 @default.
• W1968620617 hasLocation W19686206172 @default.
• W1968620617 hasOpenAccess W1968620617 @default.
• W1968620617 hasPrimaryLocation W19686206171 @default.
• W1968620617 hasRelatedWork W2002120878 @default.
• W1968620617 hasRelatedWork W2003938723 @default.
• W1968620617 hasRelatedWork W2047967234 @default.
• W1968620617 hasRelatedWork W2118496982 @default.
• W1968620617 hasRelatedWork W2364998975 @default.
• W1968620617 hasRelatedWork W2369162477 @default.
• W1968620617 hasRelatedWork W2439875401 @default.
• W1968620617 hasRelatedWork W4238867864 @default.
• W1968620617 hasRelatedWork W2519357708 @default.
• W1968620617 hasRelatedWork W2525756941 @default.
• W1968620617 hasVolume "20" @default.
• W1968620617 isParatext "false" @default.
• W1968620617 isRetracted "false" @default.
• W1968620617 magId "1968620617" @default.
• W1968620617 workType "article" @default.